Maxim raised the firm’s price target on NervGen Pharma (NGEN) to $12 from $10 and keeps a Buy rating on the shares, citing alignment with the FDA on RESTORE, the company’s Phase 3 registrational study designed to evaluate NVG-291 for the treatment of chronic tetraplegia, and the study’s “favorable” design.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
- NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
- NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
- NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
- NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions